Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of Jupiter Neurosciences, Inc. - Common Stock
No Price
28.04.2026 22:04
Current Prices from Jupiter Neurosciences, Inc. - Common Stock
Exchange
Ticker
Currency
Last Trade
Price
Daily Change
NASDAQ
JUNS
USD
28.04.2026 22:04
0,36 USD
-0,003 USD
-0,72 %
IEX
JUNS
USD
24.04.2026 15:03
0,39 USD
-
Share Float & Liquidity
Free Float50,52 %
Shares Float18,33 M
Shares Outstanding36,28 M
Company Profile for Jupiter Neurosciences, Inc. - Common Stock Share
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease. In addition, it is developing JNS109 for amyotrophic lateral sclerosis; JNS110 for traumatic brain injury/concussion; and JNS120 for covid-19 treatment. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. The company was founded in 2016 and is headquartered in Jupiter, Florida.
